Business Context and Reporting Period
Company: PharmaCyte Biotech, Inc. (PMCB)
Filing Type: Form 8-K (Current Report)
Date of Report: August 15, 2022
Event: Entry into a Material Definitive Agreement (Cooperation Agreement) with Iroquois Master Fund Ltd. and its affiliates ("Iroquois Parties").
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Board Composition: The Board of Directors was reconstituted effective August 15, 2022. Five directors (Dr. Matthias Löhr, Dr. Raymond C.F. Tong, Thomas Liquard, Dr. Gerald W. Crabtree, and Carlos A. Trujillo) resigned.
- New Appointments: Five new independent directors were appointed: Jonathan L. Schechter, Joshua N. Silverman, Daniel Allen, Daniel S. Farb, and Jack E. Stover.
- Shareholder Ownership: As of the agreement date, the Iroquois Parties held 1,389,869 shares, representing approximately 6.7% of the Company's outstanding common stock.
- Board Size: The Board size is fixed at seven members.
Guidance, Outlook, and Agreements
Cooperation Agreement Terms:
- Standstill Provisions: The Iroquois Parties agreed to a standstill period lasting until the later of September 30, 2024, or the date neither Iroquois appointee serves on the Board. During this period, they are restricted from soliciting proxies, forming groups, seeking additional board representation, or making merger/acquisition proposals.
- Ownership Cap: The Iroquois Parties are restricted from acquiring beneficial ownership exceeding 14.9% of the Company's outstanding common stock during the Standstill Period.
- Replacement Rights: If an Iroquois appointee leaves the Board and the Iroquois Parties maintain at least 2% ownership, they retain the sole right to designate a replacement.
- Director Compensation: New directors receive a quarterly cash retainer of $12,500 (pro-rated), 334 shares of common stock, and a stock option to purchase 334 shares (fully vested upon grant).
Management Commentary: The resignations of the former directors were not due to any disagreement with the Company but were part of the Cooperation Agreement deemed to be in the best interests of the Company.
Investor Verification Checklist
- Verify the full text of the Cooperation Agreement (Exhibit 10.1) for specific conditions regarding the Standstill Period and ownership caps.
- Confirm the voting status and proxy solicitation plans for the 2022 Annual Meeting of Shareholders.
- Review the Director Offer Letters (Exhibit 10.2) for detailed compensation terms and service conditions.
- Monitor future filings for any changes in the Iroquois Parties' beneficial ownership percentage relative to the 14.9% threshold.